CDSCO approves Trastuzumab Deruxtecan for first-line HER2-positive breast cancer EP News Bureau Jun 11, 2026 Approval expands indication for Trastuzumab Deruxtecan in combination with Pertuzumab for adults with unresectable or metastatic…
FDA grants priority review to Genentech’s Inavolisib EP News Bureau May 29, 2024 The priority review is granted for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
BDR Pharma launches generic Palbociclib for breast cancer treatment EP News Bureau Jan 13, 2023 The drug will be made available in three strengths i.e. – 125 mg, 100 mg and 75 mg capsules priced at Rs 3,150 for 75 mg; Rs 3,600…
